- Akadeum Life Sciences has launched the Akadeum CDMO Alliance™, naming Charles River and ElevateBio as inaugural members with early access to its microbubble-based cell separation technologies.
- The partnership aims to reduce manufacturing costs and timelines in cell therapy production, with microbubble workflows offering up to 40% savings.
Akadeum Life Sciences has launched the Akadeum CDMO Alliance™, a new consortium designed to support innovation in cell therapy manufacturing by integrating microbubble-based cell separation technologies with partner CDMOs. Charles River and ElevateBio have been named as the first two members of the alliance. The initiative aims to reduce costs, accelerate production timelines and improve access to cell therapies.
The collaboration brings together Who, What, When and Why from the announcement: Akadeum, a company focused on buoyant cell separation, established the alliance to provide CDMOs with early access to emerging technologies. The company stated that microbubbles can deliver up to 40% savings in manufacturing workflow costs. Members of the alliance will have early access to new kits under development and tailored technical engagement from Akadeum’s R&D and support teams.
Charles River and ElevateBio were selected as inaugural members based on existing collaborations. Both companies have generated data demonstrating reduced impurities and high T-cell potency using Akadeum’s microbubble technology. ElevateBio recently presented findings showing that buoyant cell separation offers a viable alternative to traditional methods and supports scalability in cell therapy manufacturing. Charles River has incorporated Akadeum’s products into its Cell Therapy Flex Platform, used for autologous CAR-T and TCR-T workflows.
The announcement outlines how the alliance will function, offering its members insight into Akadeum’s development pipeline, dedicated technical support and access to customised training. Membership will be limited, with plans to expand to five CDMOs by early 2026. Akadeum said the alliance is intended to support a smoother transfer from process development to commercial manufacturing.
“Akadeum has continually set the bar for cell separation improvements to drive cell therapy forward. The alliance is designed to unite technologies and capabilities across trusted CDMO partners.”
Brandon McNaughton, CEO of Akadeum
The company noted that its microbubble kits can complete cell separation in under an hour, reduce run-failure risk, and allow up to three manufacturing starts on fewer production lines. These features, Akadeum said, position the technology as a tool for CDMOs seeking efficiencies without new equipment or additional laboratory footprint.
